Results after first-line treatment of non-Hodgkin and Hodgkin lymphoma treated between 2013 and 2022 in Department of Hematooncology, Faculty Hospital in Ostrava, Czech Republic.

Abstract

Lymphomas are a heterogenous group of blood malignancies, having different histopathological, immunohistochemical and clinical features, as well as different prognosis and therapy. In our retrospective analysis, we put forward results after 1^st line of therapy of 668 patients with non-Hodgkin lymphoma (NHL) and 142 patients with Hodgkin lymphoma (HL) treated between 2013 and 2022 in Department of Hematooncology, Faculty Hospital in Ostrava, Czech Republic. We focus mainly on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and HL with major interest in overall response rate (ORR), progression free survival (PFS) and overall survival (OS). In the DLBCL group, 82% (221/274) patients received R-CHOP/ R-CHOP-like treatment. The complete remission (CR) rate in this cohort was 80% (177/221), median PFS and OS was 122 months and five-year PFS and OS was 61% and 66%, respectively. Low IPI risk was associated with better PFS and OS, which was also partially true for GCB (Germinal Centre B-cell like) immunophenotype. Of 134 patients with FL, 60% (80/134) received chemotherapy in combination with anti-CD20 monoclonal antibody as 1^st line treatment, with 95% ORR (76/80) and 76% CR (62/80). The median PFS and OS was not reached for the whole group. The five-year PFS and OS was 63% and 86%, respectively. Better survival rate was observed in patients with localized Lugano stage at the time of diagnosis and low FLIPI. Of 142 patients with HL, 96% (136/142) had classical HL (cHL). For this group, median PFS and OS was not reached. The five-year PFS and OS was 75% and 86%, respectively. The respective five-year PFS and OS in early stages was 94% and 100%, in intermediate stages 84% and 90%, in advanced stages 68% and 81%. Our observed results of lymphoma patients with standard treatment are comparable to results from clinical trials and other authors’ analyses from daily clinical practice.